A US court ruling finds reporting of many clinical trials of unapproved drugs in breach of the law. But responses to the ruling are uncertain.
Increasing quality and transparency of preclinical data: an opportunity for publication professionals?
An article in the MAP newsletter examines how publication professionals could help to increase preclinical publishing standards.
Missed the 14th Annual Meeting of ISMPP? Read the second part of our meeting report to get up to speed!
A new study from the AllTrials team sheds light on clinical trial reporting rates by non-industry sponsors.
A new, regular series in The BMJ will highlight a different unreported clinical trial every week, with the intention of improving reporting rates.